EMCDDA Home
  • EN
Search

Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU, Croatia, Turkey and Norway

Part (i) Legal framework regarding the initiation of OST by substitution medication

CountryMETHADONEHIGH DOSAGE BUPRENORPHINEBUPRENORPHINE-NALOXONE COMBINATIONSLOW-RELEASE MORPHINE
medical doctors at specialised drug treatment centres specialised medical doctorsany medical doctorother providermedical doctors at specialised drug treatment centres specialised medical doctorsany medical doctorother providermedical doctors at specialised drug treatment centres specialised medical doctorsany medical doctorother providermedical doctors at specialised drug treatment centres specialised medical doctorsany medical doctorother provider
Belgium (Flemish community)YYYYY
Belgium (French community)YYYY
BulgariaYY(iii)YY(iii)
Czech Republic(1)YYYYY
DenmarkYYY(i)YYY(i)YYY(i)
GermanyYYYYYYYYY
EstoniaYYY
Ireland(2)YYYY
GreeceYYY
Spain(3)YY
FranceYY(ii)YYYY
ItalyYYYYYYYY
CyprusY(ii)YY(ii)Y(ii)Y(ii)
LatviaYYYYY
LithuaniaYY(iii)YY(iii)YY(iii)
LuxembourgYYYYYYYY
HungaryYYY
Malta
NetherlandsYYYY(iv)YYYYYYYYY
AustriaYYYYYY
PolandY
PortugalYYYYYYYY
RomaniaYYYY
SloveniayYYY(i)YY
SlovakiaYYY
FinlandYYY
Sweden
United KingdomYYYY(i)YYYY(i)YYYY(i)YYYY(i)
CroatiaYYYY
Turkey(4)
NorwayYYY
 

Notes:

'Y' indicates whether a specific provider is involved in initiating opioid substitution treatment.

Where a specific provider is not allowed to initiate a specific treatment, the table entry is left empty. Exception for Malta, Sweden and Croatia for which data were not available .

'Specialized medical doctors' refers to specifically trained or accredited office-based medical doctors or general practitioners practicing outside specialised drug treatment centres.

'Any medical doctor' refers to office-based medical doctors practicing outside specialised drug treatment centres.

(1) In Czech Republic any medical doctor can prescribe methadone, however it has not been marketed yet as proprietary (commercial) medicine, thus currently methadone is only available in specialised centres.

(2) In Ireland, buprenorphine is provided for substitution in a pilot programme. It does not come under the same legal framework as methadone but does come under the controlled drug legislation.

(3) In Spain, high dosage buprenorphine is not commercially available.

(4) In Turkey Buprenorphine-Naloxone combination treatment is available since 2009.

Other providers:

(i) Prison and probation services

(ii) Doctors based in public hospitals

(iii) Psychiatrists

(iv) Medical nurses

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Structured Questionnaire on 'treatment programmes' (SQ27P1), submitted by NFPs.

Answers from the legal correspondents of the European Legal Database on Drugs (ELDD) to a EMCDDA survey on the legal framework of substitution treatment (2006). See also ELDD topic overview.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013